| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Biologics | Digestive System | ||
Phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Biologics | Digestive System | ||
Phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Biologics | Digestive System |
Recent Updates
Recently added Catalysts
Shattuck Labs, Inc.$6.64
-0.39 (-5.55%)
D 31Pipeline Score Richly Valued Biotech · Clinical
Market Cap
467.75 M
EPS
-0.64
P/E Ratio
-
Value Trade
1.78 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
10.95 M
Operating CF
-13.42 M
Total Assets
102.12 M
Total Liabilities
6.29 M
Equity
95.83 M
D/E Ratio
12,345
-6.44 %
Week
-21.99 %
1 Month
52.5 %
3 Month
221.05 %
6 Month
-77.53 %
5 Year
-72.4 %
All Time
Cash Data
Cash Position
102.12 M
Monthly Burn
4.47 M
Runway
20.9 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
1.73 M
52 Week Range
0.71 - 8.33
% held by Insiders
13.54 %
% held by Institutions
62.25 %
Enterprise Value
380.22 M
Total Shares
75.42 M
Short %
11.03 %
Float Shares
53.77 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Shattuck Labs, Inc.
284Total events
7Upcoming
30Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 7
Event history 277
Q3 2026
◆Trial InitiationSL-325Trial
Phase 2 trial in Crohn's disease expected to initiate
Crohn's diseasesource ↗
Jun 10, 2026
▼Equity OfferingCorporate
Pricing of $75 million public offering of common stock and pre-funded warrants
Jun 9, 2026
▲Equity OfferingCorporate
Exercise of approximately 50.6 million common stock warrants for aggregate gross proceeds of approximately $54.9 million
Jun 9, 2026
▲Runway Guidance UpdateCorporate
Cash runway guidance extended into 2029 based on current operational plans and warrant proceeds
Jun 8, 2026
◆Oral PresentationSL-325Presentation
Investor call and webcast presenting Phase 1 clinical data for SL-325
inflammatory and immune-mediated diseasessource ↗
Jun 8, 2026
May 7, 2026
▲Enrollment CompleteSL-325Trial
Phase 1 trial of SL-325 enrollment complete
healthy volunteerssource ↗
May 7, 2026
●IND Enabling CompletePreclinical
Lead bispecific antibody enters IND-enabling activities
inflammatory and immune-mediated diseasessource ↗
Q2 2026
◆Enrollment CompleteSL-325Trial
Phase 1 enrollment completion expected
inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseasessource ↗
Q2 2026
Drug Pipeline Intelligence
D31
Pipeline Score $47M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.1x
rNPV / MCap Top 37%
Micro Cap (rank 575 of 911)
Percentile RankShattuck Labs, Inc. faces pipeline headwinds (31/100), with $195M risk-adjusted pipeline value, led by SL-325 in Healthy Volunteers (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SL-325 Monoclonal antibody | Healthy Volunteers | Phase 1 | NCT07158437 | 13% | $126M | ACTIVE NOT_RECRUITING | 72 | AVERAGE | C (57) | Jul 1, 2026 | LOW_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SL-325 | inflammatory diseases | Phase 1 | 2026-06-08 | 3.7% of participants developing antidrug antibodies; Complete blockade of TL1A binding for over 3 months; 72 participants enrolled; Doses ranging from 0.1 mg/kg to 30.0 mg/kg; Complete DR3 occupancy observed at doses of 0.1 mg/kg and higher; Durable inhibition of TL1A binding for more than 10 weeks; Accumulation ratio of 1.64-1.75 Read More | Shattuck Labs Announces Phase 1 Results for SL-325 | |
SL-325 | inflammatory diseases | Phase 1 | 2026-06-08 | 3.7% of participants developing antidrug antibodies; Complete blockade of TL1A binding for over 3 months; 72 participants enrolled; Doses ranging from 0.1 mg/kg to 30.0 mg/kg; Complete DR3 occupancy observed at doses of 0.1 mg/kg and higher; Durable inhibition of TL1A binding for more than 10 weeks; Accumulation ratio of 1.64-1.75 Read More | Shattuck Labs Announces Phase 1 Results for SL-325 | |
SL-325 | inflammatory diseases | Phase 1 | 2026-06-08 | 3.7% of participants developing antidrug antibodies; Complete blockade of TL1A binding for over 3 months; 72 participants enrolled; Doses ranging from 0.1 mg/kg to 30.0 mg/kg; Complete DR3 occupancy observed at doses of 0.1 mg/kg and higher; Durable inhibition of TL1A binding for more than 10 weeks; Accumulation ratio of 1.64-1.75 Read More | Shattuck Labs Announces Phase 1 Results for SL-325 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in STTK
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
STTK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
STTKShattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
Shattuck Labs, Inc. has announced the pricing of a public offering of approximately $75 million, consisting of 10,879,376 shares at $4.00 each and pre-funded warrants. The offering is expected to close on June 11, 2026, pending customary conditions. Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor are the joint bookrunning managers for this offering.
Read more →STTK▲ +9.5%on this news· ran to +27% by day 3shared move
Shattuck Labs, Inc. Announces Proposed Public Offering
Shattuck Labs, Inc. has announced a proposed public offering of its common stock, with the option for certain investors to purchase pre-funded warrants. The offering is subject to market conditions, and the company has engaged several prominent underwriters. Shattuck Labs specializes in developing innovative therapies for inflammatory and immune-mediated diseases.
Read more →STTK▲ +9.5%on this news· ran to +27% by day 3shared move
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
Shattuck Labs has announced the exercise of approximately 50.6 million common stock warrants, resulting in expected gross proceeds of about $54.9 million. This follows the exercise of over 5 million warrants earlier this year. The company reports having sufficient cash reserves to support its operations until 2029, based on current plans.
Read more →STTK▼ -14.8%on this newsshared move
Shattuck Labs Announces Phase 1 Results for SL-325
Shattuck Labs announced positive Phase 1 results for SL-325, its lead DR3 blocking antibody. The trial demonstrated a favorable safety profile and a potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies. SL-325 achieved complete blockade of TL1A binding for over three months, supporting its efficacy for treating inflammatory diseases. A Phase 2b trial in Crohn's disease is expected to begin in Q3 2026.
Read more →STTKShattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
Shattuck Labs will host an investor call on June 8, 2026, to discuss Phase 1 clinical data for SL-325, a DR3 blocking antibody. The presentation will cover safety, pharmacokinetics, and immunogenicity results, along with a pipeline update. Key executives will present and participate in a Q&A session.
Read more →STTK▼ -6.3%on this news
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
Shattuck Labs has completed enrollment in its Phase 1 clinical trial of SL-325, with data expected in the second quarter of 2026. The company plans to initiate a Phase 2 trial for Crohn's disease in the third quarter of 2026, contingent on positive Phase 1 results. Financially, Shattuck reported a net loss of $14.8 million for the first quarter of 2026, while maintaining a strong cash position.
Read more →STTK▲ +7.8%on this news· ran to +27% by day 1
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
Shattuck Labs reported its financial results for Q4 and full year 2025, highlighting the ongoing Phase 1 trial of SL-325, with data expected in Q2 2026. The company anticipates initiating a Phase 2 trial for Crohn's disease in Q3 2026. Despite a net loss of $12.6 million for Q4, recent capital raises have improved their financial standing.
Read more →STTK▼ -5.4%on this news
Shattuck Labs Announces Participation in Upcoming March Investor Conferences
Shattuck Labs, a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences. CEO Taylor Schreiber will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, and engage in one-on-one meetings at the Leerink Partners 2026 Global Health Care Conference on March 10-11, 2026. The company is focused on developing first-in-class DR3-blocking antibodies for inflammatory diseases.
Read more →STTK▲ +5.6%on this news
Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium
Shattuck Labs, Inc. announced its participation in the Piper Sandler Virtual Novel Targets in Immunology Symposium scheduled for February 12-13, 2026. The company's management will engage in a fireside chat, featuring key executives discussing their innovative therapies. Notably, Shattuck is advancing SL-325, a potential first-in-class antibody targeting the DR3/TL1A pathway, currently in Phase 1 trials.
Read more →STTKShattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Shattuck Labs, Inc. announced the granting of inducement equity awards to a newly-hired non-executive officer, consisting of non-qualified stock options for 206,000 shares at an exercise price of $3.23. These options will vest over a period of time, starting in November 2026. This move aligns with Nasdaq Listing Rule 5635(c)(4) and highlights the company's ongoing commitment to attract talent.
Read more →STTKShattuck Labs to Participate in Upcoming December Investor Conferences
Shattuck Labs, Inc. announced its participation in several investor conferences in December 2025, including the Piper Sandler 37th Annual Healthcare Conference and the Evercore ISI 8th Annual HealthCONx Conference. CEO Taylor Schreiber will present at both events, discussing the company's innovative therapies targeting TNF superfamily receptors. The company is advancing its lead program, SL-325, currently in Phase 1 trials.
Read more →STTKShattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Shattuck Labs reported its third quarter 2025 financial results, highlighting the initiation of a Phase 1 clinical trial for SL-325, a novel DR3 blocking antibody. The company successfully closed a $103 million private placement to support further development. CEO Taylor Schreiber expressed confidence in advancing SL-325 into Phase 2 trials, backed by a strong cash position.
Read more →STTKShattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel
Shattuck Labs, Inc. will participate in the Wedbush Securities KOL panel discussing insights from the UEGW Conference 2025. The session features key opinion leader Marla Dubinsky and will be moderated by analysts Martin Fan and David Nierengarten. Shattuck's CEO, Taylor Schreiber, will represent the company during this event.
Read more →STTKShattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
Shattuck Labs has successfully closed a private placement of up to $103 million, which will fund its SL-325 program through multiple Phase 2 clinical trials, including studies in Inflammatory Bowel Disease. The company has appointed two new board members, enhancing its leadership with experienced industry professionals. This financing positions Shattuck to advance its innovative therapies into 2029.
Read more →STTK▼ -11.9%on this newsshared move
Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease
Shattuck Labs has announced that its IND application for SL-325, a DR3 antagonist antibody for inflammatory bowel disease, is now effective. The company plans to begin dosing the first participant in its Phase 1 clinical trial in Q3 2025, with enrollment expected to complete by Q2 2026. The trial will evaluate the safety and pharmacokinetics of SL-325 in healthy volunteers.
Read more →STTK▲ +6.1%on this news· ran to +27% by day 3
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Shattuck Labs reported its second quarter 2025 financial results, highlighting the submission of an IND application for the SL-325 drug candidate, expected to clear in Q3 2025. The company has adequate funds, estimated at $50.5 million, to support operations into 2029 after a successful private placement. The Phase 1 clinical trial for SL-325 is set to begin enrollment in Q3 2025. However, the company experienced a net loss of $12.5 million for the quarter and a decrease in cash reserves compared to the previous year.
Read more →STTK▲ +33.3%on this news
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
Shattuck Labs announced a successful private placement financing expected to yield approximately $103 million. The funds will support the development of SL-325 through multiple Phase 2 clinical trials targeting inflammatory bowel disease and other autoimmune conditions. The company anticipates that the proceeds will sustain operations into 2029, contingent on regulatory approvals.
Read more →STTKShattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism
Shattuck Labs, Inc. announced its participation in the Leerink Partners Therapeutics Forum, focusing on its innovative SL-325 antibody targeting the DR3/TL1A pathway. The panel discussion will be led by CEO Taylor Schreiber on July 8, 2025, in Boston. SL-325 has shown promising preclinical results and is set for an IND filing in Q3 2025.
Read more →STTK▲ +9.2%on this news
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights
Shattuck Labs has announced its financial results for the first quarter of 2025, showcasing a cash balance of approximately $60.9 million that is projected to sustain operations until 2027. The company is making significant progress in its SL-325 program, with an IND filing expected in Q3 2025. Preclinical studies have demonstrated a favorable safety profile and the potential for SL-325 to achieve best-in-class clinical remission rates for inflammatory bowel disease (IBD) patients. Despite a reported net loss, the company is well-positioned for future development and growth.
Read more →STTK▼ -17.3%on this news
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
Shattuck Labs, Inc. announced its participation in the 24th Annual Needham Virtual Healthcare Conference, scheduled for April 7-10, 2025. CEO Taylor Schreiber will present on April 9, 2025, and engage in one-on-one meetings. The company is also advancing its SL-325 therapeutic, targeting inflammatory diseases, with an IND filing expected in Q3 2025.
Read more →STTKShattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
Shattuck Labs, Inc. reported its financial results for the fourth quarter and full year of 2024, highlighting key developments surrounding its lead product SL-325, a potentially first-in-class DR3 blocking antibody. The company is preparing for an IND filing scheduled for the third quarter of 2025 and has shared promising preclinical data demonstrating a favorable safety profile and high receptor occupancy. Additionally, despite a significant decrease in cash reserves year-over-year, Shattuck's current financial position is expected to support operations into 2027.
Read more →STTKShattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
Shattuck Labs has announced positive results from a GLP toxicology study of its DR3 blocking antibody SL-325 in non-human primates. The study demonstrated that SL-325 was well tolerated, with no signs of toxicity or agonism observed, supporting its potential for use in treating inflammatory bowel disease. The pharmacokinetic profile suggests that SL-325 may utilize extended dosing intervals when tested in humans. The company plans to file an Investigational New Drug application in the third quarter of 2025 and anticipates commencing Phase 1 clinical trials for SL-325 soon.
Read more →STTK▲ +5%on this news
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
Shattuck Labs, Inc. announced an upcoming oral presentation for SL-325 at the 20th Congress of the European Crohn’s and Colitis Organization (ECCO) to be held in Berlin from February 19-22, 2025. The presentation will cover IND-enabling toxicology studies of SL-325, a first-in-class DR3 blocking antibody aimed at treating inflammatory bowel diseases. Dr. Taylor Schreiber, CEO of Shattuck, will present findings that demonstrate high affinity binding and efficacy superior to TL1A antibodies. The company plans to file an Investigational New Drug application for SL-325 in Q3 2025.
Read more →STTKShattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress
Shattuck Labs, Inc. is set to present a poster at the 2025 Crohn’s and Colitis Congress in San Francisco, focusing on their investigational antibody SL-325 for inflammatory bowel disease (IBD). The presentation is scheduled for February 7, 2025, at the Moscone Center. SL-325 targets the TL1A/DR3 pathway and is part of Shattuck's efforts in developing novel therapies for autoimmune and inflammatory diseases. The poster will be accessible on the company's website post-presentation.
Read more →STTK▼ -5.2%on this news
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Shattuck Labs, a biotechnology company focused on novel therapeutics for inflammatory and immune-related diseases, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Dr. Taylor Schreiber will present a corporate update and engage in one-on-one meetings. The conference is set to take place from January 13-16, 2025, in San Francisco, California. Shattuck Labs is known for developing a first-in-class antibody for inflammatory bowel disease and advancing its lead program involving the TL1A/DR3 pathway.
Read more →STTKShattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
Shattuck Labs provided a corporate update, highlighting key milestones for 2025, including the anticipated initiation of a Phase 1 clinical trial for their lead candidate, SL-325. The company reports considerable advancements in its DR3 blocking antibody, with promising preclinical results. Cash reserves are expected to support operations through 2027, indicating financial stability. Additionally, presentations of their preclinical data are scheduled at significant medical conferences.
Read more →STTKShattuck Labs Announces Participation in Upcoming December Conferences
Shattuck Labs, Inc. (STTK) has announced its participation in two upcoming investor conferences in December 2024. The company's CEO, Dr. Taylor Schreiber, will present at the Piper Sandler 36th Annual Healthcare Conference on December 3 and will also participate in a fireside chat at the Evercore 7th Annual HealthCONx Conference on December 4. These events aim to provide investors with insight into Shattuck's ongoing developments in novel therapeutics targeting immune-related diseases and cancer.
Read more →STTK▲ +12.3%on this news
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Shattuck Labs, Inc. has reported its financial results for Q3 2024, highlighting a strategic shift towards the development of SL-325, a first-in-class DR3 blocking antibody. The company maintains a cash balance of approximately $90 million, which is expected to sustain operations through 2027. Additionally, restructuring plans have been substantially completed to streamline operations and focus on the SL-325 program. Despite the positive developments, Shattuck recorded a net loss of $16.7 million for the quarter, improved but still significant compared to the previous year.
Read more →STTK▼ -45%on this news· ran to -65% by day 3
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway Interim clinical data for SL-172154 in combination with azacitidine
Shattuck Labs has announced a strategic pipeline shift, discontinuing clinical development of SL-172154 due to its lack of meaningful overall survival improvements in recent trials. Instead, the company will focus on SL-325, a first-in-class DR3 antagonist antibody aimed at treating inflammatory bowel disease. Additionally, Shattuck has implemented a restructuring plan that will reduce its workforce by about 40% to better align with its current goals, while ensuring financial resources can sustain operations into 2027.
Read more →STTK▼ -5.3%on this news· ran to -22% by day 3
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Shattuck Labs has reported promising interim data from its Phase 1B clinical trial of SL-172154, showing improved complete remission rates for HR-MDS and TP53m AML patients when combined with Azacitidine. The company has initiated enrollment in a randomized, controlled dose-expansion cohort for frontline HR-MDS patients and has received Orphan Drug Designation from the FDA for SL-172154 targeting AML. Despite a slight increase in net loss from the previous year, the company remains optimistic about its cash runway extending into 2026.
Read more →STTKShattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
Shattuck Labs, Inc. has announced its participation in the upcoming BTIG Virtual Biotechnology Conference, scheduled for August 5-6, 2024. Company management, including CEO Dr. Taylor Schreiber, will partake in a fireside chat and one-on-one meetings with conference attendees. Shattuck is focused on pioneering bi-functional fusion proteins for cancer and autoimmune treatments, with its lead program SL-172154 currently in Phase 1 trials. A live webcast will be available for those interested in the fireside chat.
Read more →STTKShattuck Labs Announces Addition to Russell 2000 and Russell 3000 Indexes
Shattuck Labs, Inc. (Nasdaq: STTK) has been added to the Russell 2000 and Russell 3000 Indexes as of July 1, 2024. This move reflects the company's progress in 2024, particularly in advancing its clinical program for SL-172154, aimed at treating HR-MDS and TP53m AML. The CFO emphasized that they are moving forward quickly with this promising therapeutic approach and anticipate further updates on clinical trials.
Read more →STTK▼ -9.5%on this news· ran to -39% by day 3
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP5
Shattuck Labs has announced updated interim data from its Phase 1B dose expansion trial of SL-172154 in combination with Azacitidine for patients with higher-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia. The data showed a promising 67% objective response rate in HR-MDS patients and an initial complete remission rate of 58%, while the safety profile appeared manageable. As enrollment for the randomized cohort continues, Shattuck is focusing its development on these high-need indications and expects to advance regulatory discussions later this year.
Read more →STTKShattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
Shattuck Labs announced that the U.S. FDA has granted orphan drug designation to its lead candidate SL-172154 for the treatment of acute myeloid leukemia (AML). This designation emphasizes the need for new therapy options for AML, which currently has limited treatments and poor patient outcomes. The company plans to provide data from ongoing Phase 1 clinical trials and is preparing for further study developments. The orphan drug designation may provide Shattuck with significant advantages, including market exclusivity and financial benefits for clinical trials.
Read more →STTKShattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
Shattuck Labs, Inc. has announced an investor call set for June 14, 2024, to discuss interim safety and efficacy data from a Phase 1B clinical trial of SL-172154 combined with Azacitidine in patients with frontline higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant acute myeloid leukemia (AML). The call, featuring lead investigator Dr. Naval G. Daver, will provide insights into the ongoing research and aims to inform stakeholders about the future of the treatment. Interested participants must register in advance to access the live webcast.
Read more →STTK▼ -18.1%on this news
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress
Shattuck Labs announced promising data from the Phase 1B trial of SL-172154 in combination with Azacitidine for higher-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia patients. The trial showed an encouraging complete response rate and acceptable safety profile. Additional data will be presented at the EHA 2024 Congress, highlighting the potential therapeutic benefits of SL-172154 for these populations. However, there were also some serious adverse events noted, including two cases linked to the treatment.
Read more →STTKShattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
Shattuck Labs reported its financial results for the first quarter of 2024, highlighting progress in its clinical trials, including the enrollment of TP53 mutant Acute Myeloid Leukemia patients and plans for a randomized Phase 1B study in higher-risk Myelodysplastic Syndromes. The company is expected to present updated combination data at the upcoming European Society of Hematology Annual Meeting in June 2024. Alongside, Shattuck is developing its preclinical pipeline and has established a collaboration with Ono Pharma for further research.
Read more →STTKShattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Shattuck Labs announced the oral presentation of preclinical data at the AACR Annual Meeting 2024, highlighting the role of TRIM7 inhibition in combating acquired resistance to immune checkpoint therapy. The findings suggest that targeting TRIM7 could enhance the effectiveness of PD-1 inhibitors. This presentation underscores Shattuck's ongoing efforts to address significant unmet needs in oncology. The data were presented by Dr. George Fromm, and further information will be made available on Shattuck's investor website.
Read more →STTKShattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
Shattuck Labs, Inc. (NASDAQ: STTK) announced its participation in the 23rd Annual Needham Virtual Healthcare Conference scheduled for April 8-11, 2024. The company's CEO, Dr. Taylor Schreiber, will present during a live fireside chat format, which reveals the firm’s ongoing commitment to engage with investors and the public regarding its clinical-stage biopharmaceutical advancements. This initiative reflects Shattuck's efforts to drive awareness of its innovative therapies for cancer and autoimmune diseases.
Read more →STTKShattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors AUSTIN, TX & DURHAM, NC
Shattuck Labs has announced the appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors, effective March 1, 2024. Both appointees bring extensive experience in drug development and biotechnology, which the company anticipates will be crucial as it advances its lead therapy, SL-172154, into late-stage clinical trials. The leadership changes occur amid expectations for clinical updates in the coming months and aim to bolster Shattuck's strategic objectives in developing novel therapeutics for cancer and autoimmune diseases.
Read more →STTKShattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
Shattuck Labs reported positive financial results for Q4 and full-year 2023, highlighting the progress of its SL-172154 clinical trials in various cancer indications. The company announced positive topline data from its ongoing Phase 1A/B trial in higher-risk myelodysplastic syndromes and acute myeloid leukemia, as well as interim results from its ovarian cancer studies. Shattuck also completed its Phase 1B dose-expansion for these trials and entered into a strategic collaboration with Ono Pharmaceutical for new treatment development. Additionally, the recent $50 million funding will extend its cash runway through 2026.
Read more →STTKShattuck Labs Announces Participation in Upcoming March Conferences
Shattuck Labs, Inc. has announced its participation in several investor conferences throughout March 2024, including the TD Cowen Annual Health Care Conference and the Citi Biotech C-Suite Fireside Chat Series. CEO Dr. Taylor Schreiber and CFO Andrew Neill will represent the company, discussing their innovative bi-functional fusion proteins aimed at treating cancer and autoimmune diseases. A live webcast of the presentations will be available, reinforcing the company's commitment to transparency and investor engagement. Additionally, Shattuck's lead program is currently in multiple Phase 1 trials, highlighting its ongoing research efforts.
Read more →STTK▼ -5.4%on this news
Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases
Shattuck Labs has announced a worldwide collaboration with Ono Pharmaceutical to develop bifunctional fusion proteins aimed at treating autoimmune and inflammatory diseases. Under the agreement, Shattuck will receive an upfront payment and has the potential to earn up to $227 million in milestone payments. Ono will fund the research and development expenses, while Shattuck will lead the discovery of specific compounds from its pipeline. This partnership aligns with Shattuck's strategy to leverage its expertise in protein engineering and expand its clinical offerings.
Read more →STTK▲ +14.9%on this news
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024
Shattuck Labs, a clinical-stage biotechnology company, has provided a corporate update outlining key achievements from 2023 and future milestones for 2024. The company highlighted safety and efficacy data for their investigational therapy SL-172154, which shows promise for treating various cancers. A recent $50 million financing is set to support ongoing clinical trials and development initiatives. Shattuck anticipates delivering more trial data throughout 2024, focusing on significant unmet medical needs in patients with higher-risk myelodysplastic syndromes and acute myeloid leukemia.
Read more →STTKShattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
Shattuck Labs, Inc. (NASDAQ: STTK) will present a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco from January 8-11, 2024. CEO Taylor Schreiber, M.D., Ph.D., will lead the presentation on January 11. The conference is significant for the biotech community, and a live webcast will be available for those unable to attend. Shattuck specializes in creating bi-functional fusion proteins to treat cancer and autoimmune diseases, with ongoing evaluation of its lead program in multiple Phase 1 trials.
Read more →STTKShattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
Shattuck Labs, Inc. has announced a registered public offering of 4,651,163 shares of common stock priced at $6.45 each, alongside a private placement of 3,100,823 pre-funded warrants. The combined gross proceeds are expected to reach approximately $50 million, which will be allocated for the development of pipeline candidates and general corporate purposes. The offering is expected to close by December 26, 2023, pending customary closing conditions. The company is at the forefront of developing bi-functional fusion proteins for cancer and autoimmune diseases, with its lead program undergoing Phase 1 trials.
Read more →STTK▲ +130.3%on this news· ran to +230% by day 1
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53
Shattuck Labs has reported positive initial topline data from its Phase 1 A/B trial of SL-172154 combined with Azacitidine in patients with frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant Acute Myeloid Leukemia (AML). The results indicate a 79% objective response rate in HR-MDS patients and a 64% complete response rate. Additionally, in TP53 mutant AML patients, 27% achieved an initial complete response. The drug demonstrated an acceptable safety profile and showed promise for further improving response rates as treatment continues.
Read more →STTKShattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023
Shattuck Labs, a clinical-stage biotechnology company, announced an investor call to present initial clinical trial data from its Phase 1A/B dose-expansion cohorts targeting frontline higher-risk myelodysplastic syndromes (HR-MDS) and TP53m acute myeloid leukemia (AML). Scheduled for December 13, 2023, at 8:00 a.m. ET, the call will also review dose-escalation data presented at the 2023 American Society of Hematology Annual Meeting. This event highlights the company's ongoing advancements in biologic medicines designed for cancer treatment.
Read more →STTK▲ +10.1%on this news
Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference
Shattuck Labs, Inc. has announced its participation in the upcoming 6th Annual Evercore ISI HealthCONx Conference scheduled for November 28-30, 2023. The company's CEO, Dr. Taylor Schreiber, will engage in a fireside chat during the conference on November 29. This event will allow Shattuck to showcase its innovative bi-functional fusion proteins aimed at treating cancer and autoimmune diseases. A live webcast of the discussion will be available, along with an archived replay for 90 days after the event.
Read more →STTK▼ -23.2%on this newsshared move
Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Shattuck Labs has reported encouraging interim data from its Phase 1B clinical trial of SL-172154 combined with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer, suggesting a favorable response rate. The company also noted successful enrollment in clinical cohorts for relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes. Upcoming presentations at the American Society of Hematology Annual Meeting will further illuminate the potential of their therapies. However, further data is necessary to fully assess the long-term efficacy and safety of SL-172154.
Read more →STTK▲ +14.1%on this newsshared move
Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023
Shattuck Labs, Inc. has announced that it will report its third-quarter 2023 financial results on November 9, 2023. This will include a general business overview and the event will feature company executives such as the CEO, CFO, and CMO. The focus will be on their development of bi-functional fusion proteins for cancer and autoimmune disease treatments. The lead program, SL-172154, is currently in multiple Phase 1 trials.
Read more →STTKShattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting
Shattuck Labs has announced promising topline results from its Phase 1 A/B trial of SL-172154, a novel treatment for acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS). Data indicate both monotherapy and combination therapy with azacitidine show anti-leukemic activity and a favorable safety profile. The findings will be presented at the upcoming ASH Annual Meeting, highlighting SL-172154's therapeutic potential for patients who have limited treatment options. The company aims to advance the clinical development of this investigational treatment based on the positive results observed.
Read more →STTK▼ -8.6%on this news
Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Shattuck Labs reported its financial results for Q2 2023, highlighting significant progress in clinical trials for SL-172154, particularly in ovarian cancer and acute myeloid leukemia. The company completed enrollment of the dose-escalation trial and presented encouraging data at the ASCO 2023 annual meeting. Additionally, net loss was reported at $21.3 million, but this shows an improvement over the same period last year. The firm anticipates further data releases from multiple ongoing trials in the fourth quarter of 2023.
Read more →STTK▼ -5.5%on this news
Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Shattuck Labs announced the presentation of complete dose-escalation data for SL-172154 from a Phase 1A clinical trial targeting platinum-resistant ovarian cancer. The trial highlighted a favorable safety profile and optimal dosing at 3 mg/kg, where maximal target engagement was achieved. The company anticipates sharing initial data from ongoing combination trials in mid-2023.
Read more →STTK▲ +5.6%on this news
Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights
Shattuck Labs reported its financial results for the first quarter of 2023, highlighting significant clinical progress with the SL-172154 trials. Complete data from a Phase 1A trial in platinum-resistant ovarian cancer is to be presented at the 2023 ASCO annual meeting, alongside initial data from several ongoing trials expected in the second half of the year. The company continues to experience steady enrollment in its trials for both acute myeloid leukemia and higher-risk myelodysplastic syndromes, reflecting robust interest in its clinical programs. However, the company reported a net loss of $20.7 million for the quarter, indicating financial pressures.
Read more →STTKShattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference
Shattuck Labs, Inc. has announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, scheduled for April 19, 2023. The presentation will feature CEO Taylor Schreiber, M.D., Ph.D., and CFO Andrew Neill, M.B.A. The event will include a fireside chat format, allowing for an interactive discussion regarding the company's advancements in bi-functional fusion proteins targeting cancer and autoimmune diseases. A live webcast of this session will be offered, with a replay available for up to 90 days following the event.
Read more →STTK▲ +8.9%on this news
Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Shattuck Labs presented promising preclinical data at the 2023 AACR Annual Meeting regarding its CD20-targeted GADLEN platform. The data showed effective rapid depletion of B cells in humanized mice and non-human primates, indicating strong therapeutic potential for autoimmune diseases. Notably, the compound was well tolerated, suggesting a favorable safety profile. These results pave the way for clinical studies of GADLEN in treating antibody-mediated autoimmune disorders.
Read more →STTKShattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates
Shattuck Labs reported its financial results for Q4 and full year 2022, highlighting key developments in its clinical pipeline. The company has initiated several Phase 1 trials for its product SL-172154, targeting ovarian cancer and blood cancers. Additionally, it announced the discontinuation of the SL-279252 program after failing to meet efficacy benchmarks. The promotion of Dr. George Fromm and Dr. Suresh de Silva to Chief Scientific Officers reinforces Shattuck's strategic focus on advancing its clinical research agenda.
Read more →STTKShattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023
Shattuck Labs, a clinical-stage biotechnology company, will report its fourth-quarter and full-year 2022 financial results on February 23, 2023. The earnings call will feature CEO Taylor Schreiber and other executives, providing a general business overview. Shattuck Labs is noted for its innovative bi-functional fusion proteins, aimed at cancer and autoimmune disease treatment, with its lead program currently in Phase 1 trials. Investors and interested participants can join the call via a dial-in number or a live webcast.
Read more →STTKShattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference
Shattuck Labs, Inc. announced its participation in the upcoming SVB Securities Global Biopharma Conference, scheduled for February 13-16, 2023. This event aims to showcase advancements in biotechnology, specifically focusing on Shattuck's pioneering bi-functional fusion proteins. The company, which is based in Austin, Texas, and Durham, North Carolina, is advancing its lead program, SL-172154, and other therapeutic platforms aimed at treating cancer and autoimmune diseases. The company intends to use its website for investor communications and regulatory disclosures.
Read more →STTKShattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023
Shattuck Labs provided a corporate update highlighting key milestones and accomplishments in 2022, as well as expectations for 2023. The company anticipates important clinical data readouts for its lead candidate SL-172154 in both solid tumors and hematologic indications. With collaborations in place for ovarian cancer therapies and strong financial reserves, Shattuck is positioned for growth and optimism in upcoming trials.
Read more →STTK▼ -6.8%on this news
Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights
– Completed enrollment in Phase 1 dose-escalation clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer; complete data expected midyear 2023 – – Dosed first patient in ongoing Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubici
Read more →STTKShattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Data from two distinct GADLEN product candidates, one targeting CD20 and another targeting B7-H3, enhanced γδT cell killing of tumor cells, demonstrating preclinical proof-of-concept in the treatment of cancer - AUSTIN, TX and DURHAM, NC, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Shat
Read more →STTKShattuck Labs Announces Participation in Upcoming November Conferences
AUSTIN, TX and DURHAM, NC, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with ca
Read more →STTKShattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022
AUSTIN, TX and DURHAM, NC, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with ca
Read more →STTK▲ +10%on this news
Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12
AUSTIN, TX & DURHAM, NC, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with canc
Read more →STTKShattuck Labs Announces Participation in Upcoming September Conferences
AUSTIN, TX & DURHAM, NC, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with can
Read more →STTKShattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights
– Enrollment of Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in platinum-resistant ovarian cancer expected to begin in Q3’2022 with initial combination data expected in 1H’2023 – – Dose escalation ongoing for Phase 1 clinical trial of SL-172154
Read more →STTK▲ +8.3%on this news
Shattuck Labs Reports First Quarter 2022 Financial Results and Recent Business Highlights
– Dose escalation ongoing in Phase 1 clinical trial of SL-172154 in platinum-resistant ovarian cancer; combination trial with liposomal doxorubicin on track to begin in 2H’2022; full dose-escalation data in monotherapy and initial data in combination both expected in 1H’2023 – –
Read more →STTKShattuck Labs Presents Preclinical Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting
- SL-9258 (TIGIT-Fc-LIGHT) combined with anti-PD(L)1 broadened anti-tumor activity of the checkpoint antibodies in aggressive CPI-resistant tumors - - Butyrophilin heterodimeric fusion proteins from Shattuck’s GADLEN platform showed enhanced tumor cell killing targeting CD19 and
Read more →STTKShattuck Labs Announces Participation in Upcoming 21st Annual Needham Virtual Healthcare Conference
AUSTIN, TX and DURHAM, NC, April 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and a
Read more →STTKShattuck Labs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
– Presented positive initial dose-escalation clinical data for SL-172154, including high target occupancy, dose-dependent immune activation, and unique safety profile in heavily pretreated cancer patients – – Presented positive initial dose-escalation clinical data for SL-279252
Read more →STTKShattuck Labs to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
AUSTIN, Texas and DURHAM, N.C., March 09, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients w
Read more →STTK▼ -5.7%on this news
SHATTUCK LABS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against Shattuck Labs, Inc. in the United States District Court for the Eastern District of New York
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK) in the United States District Court for the Easte
Read more →STTKShattuck Labs Announces Participation in Upcoming 11th Annual SVB Leerink Global Healthcare Conference
AUSTIN, TX and DURHAM, NC, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with ca
Read more →STTK▼ -6.5%on this news
Shattuck Labs Announces Participation in Upcoming January Investor Conferences
AUSTIN, TX and DURHAM, NC, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and au
Read more →STTK▲ +7%on this news
Shattuck Labs to Present at TIGIT Therapies Digital Summit 2021
AUSTIN, TX and DURHAM, NC, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with ca
Read more →STTK▼ -28.6%on this news
Shattuck Labs Announces Preliminary Clinical Data from Ongoing Phase 1 Clinical Trials of ARC Fusion Proteins SL-172154 and SL-279252
– SL-279252 (PD1-Fc-OX40L) demonstrates anti-tumor activity and evidence of dose-dependent immune activation in heavily pretreated, checkpoint experienced patients – – SL-172154 (SIRPα-Fc-CD40L) demonstrates high CD47 target occupancy and CD40 target engagement and evidence of d
Read more →STTK▼ -28.6%on this news
Shattuck Labs Reports Third Quarter 2021 Financial Results and Recent Business Highlights
– Announced initial Phase 1 dose-escalation data from SL-172154 in ovarian cancer and SL-279252 in solid tumors at the Society for Immunotherapy of Cancer (SITC) annual meeting; both clinical trials remain ongoing – – SL-279252 (PD1-Fc-OX40L) demonstrates anti-tumor activity and
Read more →STTKShattuck Labs to Host Conference Call and Webcast Highlighting Data Presented at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
– Event scheduled for Friday, November 12, 2021 at 8:00 a.m. ET – AUSTIN, TX and DURHAM, NC, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a n
Read more →STTKShattuck Labs Announces Participation in Upcoming November Investor Conferences
AUSTIN, TX and DURHAM, NC, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with ca
Read more →STTKShattuck Labs Announces Changes to its Board of Directors Shattuck Labs appoints new Board member, Dr. Carrie Brownstein, M.D.; Dr. George Golumbeski, Ph.D., appointed as Chairman of the Board AUSTIN, TX and DURHAM, NC
Shattuck Labs Announces Changes to its Board of Directors Shattuck Labs appoints new Board member, Dr. Carrie Brownstein, M.D.; Dr. George Golumbeski, Ph.D., appointed as Chairman of the Board AUSTIN, TX and DURHAM, NC, October 28, 2021 Shattuck Labs, Inc. (Shattuck) (NASDAQ:
Read more →STTKShattuck Labs to Present Clinical Data on SL-172154 and SL-279252 and Preclinical Data on SL-9258 at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
AUSTIN, TX and DURHAM, NC, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with ca
Read more →STTKShattuck Labs Reports Second Quarter 2021 Financial Results and Upcoming Phase 1 Dose Escalation Data for SL-172154 and SL-279252
– Announced submission of abstracts for the initial Phase 1 dose-escalation data from both SL-172154 in ovarian cancer and SL-279252 in advanced solid tumors for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2021 – – Reported initial s
Read more →STTKShattuck Labs Announces Participation in the BTIG Biotechnology Conference
AUSTIN, TX and DURHAM, NC, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with ca
Read more →STTKShattuck Labs to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 11, 2021
AUSTIN, TX and DURHAM, NC, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with ca
Read more →STTKShattuck Labs Appoints Abhinav A. Shukla as Chief Technical Officer
AUSTIN, TX and DURHAM, NC, June 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with ca
Read more →STTKShattuck Labs Reports First Quarter 2021 Financial Results and Recent Business Highlights
– Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 – – IND filings for SL-172154 in hematologic malignancies anticipated in the second half of 2021 – – Dose-
Read more →STTKShattuck Labs Announces Participation in Upcoming May Conferences
AUSTIN, TX and DURHAM, NC, April 30, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with c
Read more →STTKShattuck Labs Announces Participation in the 7th Annual Truist Securities Life Sciences Summit
AUSTIN, Texas and DURHAM, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients w
Read more →STTKShattuck Labs Highlights Preclinical Data for SL-9258 (TIGIT-Fc-LIGHT) in an Acquired Resistance Model and Expanded Preclinical Data from the GADLEN™ Platform at AACR 2021
AUSTIN, TX and DURHAM, NC, April 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with c
Read more →STTKShattuck Labs Announces Participation in Needham’s 20th Annual Healthcare Conference
AUSTIN, TX and DURHAM, NC, April 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with c
Read more →STTKShattuck Labs Announces Promotion of Andrew R. Neill to Chief Financial Officer
AUSTIN, TX and DURHAM, NC, March 16, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with c
Read more →STTKShattuck Labs Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
– Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 – – Dose-escalation data from Phase 1 clinical trial for lead partnered PD-1 checkpoint inhibitor, SL-27925
Read more →STTKShattuck Labs to Present Two Posters at the 2021 American Association for Cancer Research (AACR) Annual Meeting
AUSTIN, TX and DURHAM, NC, March 11, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with c
Read more →STTKShattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day
AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with canc
Read more →STTKShattuck Labs to Present at H.C. Wainwright BioConnect 2021 Conference
AUSTIN, TX and DURHAM, NC, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with ca
Read more →STTKShattuck Labs to Present at 39th Annual J.P. Morgan Healthcare Conference
AUSTIN, TX and DURHAM, NC, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with ca
Read more →STTKShattuck Labs Added to Russell 2000 and 3000 Indexes
AUSTIN, TX and DURHAM, NC, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with ca
Read more →STTKShattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference
AUSTIN, TX and DURHAM, NC, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with ca
Read more →STTKShattuck Labs Reports Third Quarter 2020 Financial Results and Recent Business Highlights
– Initiated Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), for the treatment of ovarian cancer – – Completed initial public offering in October 2020 raising approximately $232.3 million in gross proceeds and extending cash run
Read more →STTKShattuck Labs Announces Preclinical Proof of Concept Study on Gamma Delta T Cell Engager, GADLEN™, Platform at SITC 2020
AUSTIN, TX and DURHAM, NC, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with ca
Read more →STTKShattuck Labs to Present Virtually at Cowen 4th Annual IO Next Summit
AUSTIN, TX and DURHAM, NC, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with ca
Read more →STTKShattuck Labs to Present Poster on Gamma Delta T Cell Engager, GADLEN™, Platform at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting
AUSTIN, TX and DURHAM, NC, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with ca
Read more →Competitive Position
How STTK ranks across every disease it competes inCompetitive Position is a premium feature
See how STTK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial